Country: Malta
Language: English
Source: Medicines Authority
GEMCITABINE
Teva Pharma B.V. (utrecht) Swensweg 5, 2031 GA Haarlem, Netherlands
L01BC05
GEMCITABINE
CONCENTRATE FOR SOLUTION FOR INFUSION
GEMCITABINE
POM
ANTINEOPLASTIC AGENTS
Withdrawn
2011-05-04
1 PACKAGE LEAFLET: INFORMATION FOR THE USER GEMCITABINE TEVA 40 MG/ML CONCENTRATE FOR SOLUTION FOR INFUSION Gemcitabine READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS MEDICINE. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you. Do not pass it on to others. It may harm them, even if their symptoms are the same as yours. - If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor. IN THIS LEAFLET: 1. What GEMCITABINE TEVA 40 MG/ML CONCENTRATE FOR SOLUTION FOR INFUSION is and what it is used for 2. Before you use GEMCITABINE TEVA 40 MG/ML CONCENTRATE FOR SOLUTION FOR INFUSION 3. How to use GEMCITABINE TEVA 40 MG/ML CONCENTRATE FOR SOLUTION FOR INFUSION 4. Possible side effects 5. How to store GEMCITABINE TEVA 40 MG/ML CONCENTRATE FOR SOLUTION FOR INFUSION 6. Further information 1. WHAT GEMCITABINE TEVA 40 MG/ML CONCENTRATE FOR SOLUTION FOR INFUSION IS AND WHAT IT IS USED FOR GEMCITABINE TEVA 40 MG/ML CONCENTRATE FOR SOLUTION FOR INFUSION belongs to a group of medicines called “cytotoxics”. These medicines kill dividing cells, including cancer cells. GEMCITABINE TEVA 40 MG/ML CONCENTRATE FOR SOLUTION FOR INFUSION may be given alone or in combination with other anti-cancer medicines, depending on the type of cancer. GEMCITABINE TEVA 40 MG/ML CONCENTRATE FOR SOLUTION FOR INFUSION is used in the treatment of the following types of cancer: • non-small cell lung cancer (NSCLC), alone or together with cisplatin • pancreatic cancer. • breast cancer, togethe Read the complete document
Page 1 of 16 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Gemcitabine Teva 40 mg/ml concentrate for solution for infusion 2. QUALITATIVE AND QUANTITATIVE COMPOSITION _ _ Each ml of concentrate for solution for infusion contains 40 mg gemcitabine (as gemcitabine hydrochloride). Each 5 ml vial contains 200 mg gemcitabine (as gemcitabine hydrochloride). Each 25 ml vial contains 1 g gemcitabine (as gemcitabine hydrochloride). Each 50 ml vial contains 2 g gemcitabine (as gemcitabine hydrochloride). Excipients: sodium 3.95 mg/ml and ethanol anhydrous 395 mg/ml. For a full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Concentrate for solution for infusion. Clear, colourless or pale yellow solution. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Gemcitabine is indicated for the treatment of locally advanced or metastatic bladder cancer in combination with cisplatin. Gemcitabine is indicated for treatment of patients with locally advanced or metastatic adenocarcinoma of the pancreas. Gemcitabine, in combination with cisplatin is indicated as first line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). Gemcitabine monotherapy can be considered in elderly patients or those with performance status 2. Gemcitabine is indicated for the treatment of patients with locally advanced or metastatic epithelial ovarian carcinoma, in combination with carboplatin, in patients with relapsed disease following a recurrence-free interval of at least 6 months after platinum-based, first-line therapy. Gemcitabine, in combination with paclitaxel, is indicated for the treatment of patients with unresectable, locally recurrent or me Read the complete document